Megan M. Rowland
Research Subjects
Research Interests
Megan M. Rowland has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Erica Ollmann Saphire
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, USA
2 shared publications James E. Robinson
Department of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70118, USA
2 shared publications- Kathryn M. Hastie
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
2 shared publications - Luis M. Branco
Zalgen Labs, Germantown, MD 20876, USA
2 shared publications - Michelle Zandonatti
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
2 shared publications - Robert F. Garry
Department of Microbiology and Immunology, Tulane University Health Sciences Center, New Orleans, LA, USA
2 shared publications
Latest Publications
- 26 October 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (668) , eabq0991
A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus
Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases. Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking. Furthermore, neutralizing antibodies against LASV are rare. Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections. Structural and mechanistic analyses reveal compatible neutralizing epitopes and complementary neutralization mechanisms that offer high potency, broad range, and resistance to escape. These antibodies either circumvent or exploit specific glycans comprising the extensive glycan shield of GPC. Further, they require mammalian glycosylation, native GPC cleavage, and proper GPC trimerization. These findings guided engineering of a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery. Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.
- 26 October 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (668) , eabq0991
A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus
Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases. Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking. Furthermore, neutralizing antibodies against LASV are rare. Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections. Structural and mechanistic analyses reveal compatible neutralizing epitopes and complementary neutralization mechanisms that offer high potency, broad range, and resistance to escape. These antibodies either circumvent or exploit specific glycans comprising the extensive glycan shield of GPC. Further, they require mammalian glycosylation, native GPC cleavage, and proper GPC trimerization. These findings guided engineering of a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery. Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.
- 2 June 2017
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 356 (6341) , 923-928
Structural basis for antibody-mediated neutralization of Lassa virus
The crystal structure of an antibody–viral glycoprotein complex illuminates viral entry mechanisms and provides a blueprint for vaccine design.
- 2 June 2017
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 356 (6341) , 923-928
Structural basis for antibody-mediated neutralization of Lassa virus
The crystal structure of an antibody–viral glycoprotein complex illuminates viral entry mechanisms and provides a blueprint for vaccine design.